Drugs / BGB-B455
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06803680 | Mar 2025 → Apr 2028 expected | metastatic malignant neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-B455 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06803680 ↗ |
| Target | CLDN6 | “BGB-B455 is a bispecific antibody (BsAbs) that targets CLDN6 on tumor cells” NCT06803680 ↗ |